Efficacy of Nirmatrelvir/Ritonavir combination (Nirmatrelvir/Ritonavir)

A major study involving patients with COVID-19 infection and at least one underlying condition that puts them at risk for severe COVID-19 infection examined the impact of Paxlovid (Nirmatrelvir/Ritonavir) combination compared with placebo (dummy treatment) on the rate of hospitalization or death within 28 days of treatment.

Most patients in the study were infected with the Delta variant. Based on laboratory studies, the nematvir/ritonavir tablet combination is also expected to be active against Omicron and other variants. The study was conducted on patients who received the nematvir/ritonavir combination within 5 days of the onset of symptoms of novel coronavirus infection and who did not receive or do not wish to receive antibody treatment. Within one month of treatment, the hospitalization or death rate for patients who received the nematvir/ritonavir combination was 0.8%, compared with 6.3% for those who received placebo. There were no deaths in the nematvir/ritonavir tablets combination group and 12 deaths in the placebo group.

NematrevirThe combination of nematvir/ritonavir tablets has been launched in China. Due to its short time on the market, it has not been included in the medical insurance. The domestic price has not yet been determined. The original drug of nematvir/ritonavir tablet combination marketed overseas, the specification is nematvir 150mg + ritonavir 100mg)*30 tablets per box, the price may be around 2,000 yuan (the price may fluctuate due to the exchange rate), India The price of each box of the generic Nematvir/Ritonavir tablet combination produced by the pharmaceutical factory may be around RMB 1,000 (the price may fluctuate due to the exchange rate). The ingredients of the two drugs are basically the same. For more drug information and specific prices, please consult Yaode Medical Consultant.